Effect of phosphate binders on supplemental iron absorption in healthy subjects

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1171-1176

  Pruchnicki, Maria C ^a   Coyle, James D ^a   Hoshaw Woodard, Stacy ^a   Bay, William H ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; FERROUS SULFATE; PHOSPHATE BINDING AGENT; SEVELAMER; TUMS E X;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG EFFECT; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON ABSORPTION; IRON BLOOD LEVEL; IRON THERAPY; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ACETATES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CALCIUM CARBONATE; CROSS-OVER STUDIES; DRUG INTERACTIONS; EPOXY COMPOUNDS; FEMALE; HUMANS; INTESTINAL ABSORPTION; IRON; MALE; PHOSPHATES; POLYAMINES; POLYETHYLENES;

EID: 0036784478     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382669     Document Type: Article

References (26)

1. NKF-K/DOQI clinical practice guidelines for anemia of chronic renal disease. Am J Kidney Dis 2001;37(suppl. 1):S184-S206.
2. Bothwell TH, Charlton RW, Cook JD, Finch CA: Iron absorption, in: Iron Metabolism in Man. Oxford: Blackwell Scientific, 1979;256-283.
3. Beard JL, Dawson BS, Pinero DJ: Iron metabolism: a comprehensive review. Nutr Rev 1996;54:295-317.
4. Ekenved G: Iron absorption studies: studies on oral iron preparations using serum iron and different radioiron isotope techniques. Scand J Haematol 1976;(suppl. 28):1-97.
5. Lawson DH, Boddy K, King PC, Linton AL, Will G: Iron metabolism in patients with chronic renal failure on regular dialysis treatment. Clin Sci 1971;41:345-351.
6. Kooistra MP, Niemanstverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJM: Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation, and aluminum. Nephrol Dial Transplant 1998;13:82-88.
7. Kooistra MP, Marx JJM: The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998;13:2578-2582.
8. O'Neil-Cutting MA, Crosby WH: The effect of antacids on the absorption of simultaneously ingested iron. JAMA 1986;255:1468-1470.
9. Ekenved G, Halvorsen L, Solvell L: Influence of a liquid antacid on the absorption of different iron salts. Scand J Haematol 1976;(suppl. 28):65-77.
10. Lide DR (ed.): CRC Handbook of Chemistry and Physics. 81st ed. New York: CRC Press LLC, 2000.
11. Burke SK, Slatopolsky EA, Goldberg DI: RenaGel®, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997;12:1640-1644.
12. Forth W, Rummel W: Iron absorption: chemical properties of iron. Physiol Rev 1973;53:733-741.
13. Delmez JA, Tindira CA, Windus DW, Norwood KY, Giles KS, Nighswander TL, et al: Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102.
14. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701.
15. O'Neill-Cutting MA, Crosby WH: Blocking of iron absorption by a preliminary oral dose of iron. Arch Intern Med 1987;147:489-491.
16. Bothwell TH, Charlton RW, Cook JD, Finch CA: Measurement of iron absorption, in: Iron Metabolism in Man. Oxford, UK: Blackwell Scientific, 1979;425-438.
17. Crosby WH, O'Neill-Cutting MA: A small-dose iron tolerance test an indicator of mild iron deficiency. JAMA 1984;251:1986-1987.
18. Tinawi M, Martin KJ, Bastani B: Oral iron absorption test in patients on CAPD: comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 1996;74:291-294.
19. Joosten E, Vander Elst B, Billen J: Small-dose oral iron absorption test in anaemic and non-anaemic elderly hospitalized patients. Eur J Haematol 1997;58:99-103.
20. Jensen NM, Brandsborg M, Boesen AM, Yde H, Dahlerup JF: Low-dose oral iron absorption test: establishment of a reference interval. Scand J Clin Lab Invest 1998;58:511-520.
21. Kirk RE: Experimental Design: Procedures for the Behavioral Sciences. 2nd ed. Pacific Grove, CA: Brooks/Cole, 1982.
22. Steinijans VW, Hauschke D: Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990;28:105-110.
23. Food and Drug Administration: Guidance for Industry: Average, Population, and Individual Approaches to Establishing Bioequivalence [draft guidance]. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1999.
24. Gugler R, Allgayer H: Effects of antacids on the clinical pharmacokinetics of drugs. Clin Pharmacokinet 1990;18:210-219.
25. Tatro DS (ed.): Drug Interaction Facts 2001. St. Louis: Facts and Comparisons, 2001.
26. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB: Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991;17:544-550.